Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20020305rdf:typepubmed:Citationlld:pubmed
pubmed-article:20020305lifeskim:mentionsumls-concept:C0027055lld:lifeskim
pubmed-article:20020305lifeskim:mentionsumls-concept:C1328053lld:lifeskim
pubmed-article:20020305lifeskim:mentionsumls-concept:C0669365lld:lifeskim
pubmed-article:20020305lifeskim:mentionsumls-concept:C1517499lld:lifeskim
pubmed-article:20020305pubmed:issue2lld:pubmed
pubmed-article:20020305pubmed:dateCreated2010-1-21lld:pubmed
pubmed-article:20020305pubmed:abstractTextNitric oxide modulates the severity of myocardial ischemia-reperfusion (I/R) injury. We investigated whether cardioselective nitric oxide synthase 3 (NOS3) gene transfer could confer myocardial protection against I/R injury in pigs and examined potential molecular mechanisms. I/R injury was induced by balloon occlusion of the left anterior descending artery for 45 min followed by 4 or 72 h reperfusion. Hemodynamic and pathological changes were measured in pigs in the absence (n = 11) or presence of prior intracoronary retroinfusion of human NOS3 (AdNOS3, 5 x 10(10) PFU, n = 13) or control vector (AdRR5, 5 x 10(10) PFU, n = 11). Retrograde NOS3 gene transfer selectively increased NOS3 expression and NO bioavailability in the area at risk (AAR) without changing endogenous NOS isoform expression. At 4 h R, LV systolic (dP/dt(max)) and diastolic (dP/dt(min)) function was better preserved in AdNOS3- than in AdRR5-injected pigs (2,539 +/- 165 vs. 1,829 +/- 156 mmHg/s, and -2,781 +/- 340 vs. -2,062 +/- 292 mmHg/s, respectively, P < 0.05 for both). Myocardial infarct size (% AAR) was significantly smaller in AdNOS3 than in control and AdRR5 and associated with a significantly greater reduction in cardiac myeloperoxidase activity, a marker of neutrophil infiltration. The latter effects were sustained at 72 h R in a subset of pigs (n = 7). In the AAR, intercellular endothelial adhesion molecule-1 expression and cardiomyocyte apoptosis were significantly lower in AdNOS3. In conclusion, single myocardial NOS3 retroinfusion attenuates I/R injury, and causes a sustained reduction in myocardial infarct size and inflammatory cell infiltration. Gene-based strategies to increase NO bioavailability may have therapeutic potential in myocardial I/R.lld:pubmed
pubmed-article:20020305pubmed:languageenglld:pubmed
pubmed-article:20020305pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20020305pubmed:citationSubsetIMlld:pubmed
pubmed-article:20020305pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20020305pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20020305pubmed:statusMEDLINElld:pubmed
pubmed-article:20020305pubmed:monthMarlld:pubmed
pubmed-article:20020305pubmed:issn1435-1803lld:pubmed
pubmed-article:20020305pubmed:authorpubmed-author:Van de...lld:pubmed
pubmed-article:20020305pubmed:authorpubmed-author:CollenDesireDlld:pubmed
pubmed-article:20020305pubmed:authorpubmed-author:GillijnsHilde...lld:pubmed
pubmed-article:20020305pubmed:authorpubmed-author:VerbekenErikElld:pubmed
pubmed-article:20020305pubmed:authorpubmed-author:JanssensStefa...lld:pubmed
pubmed-article:20020305pubmed:authorpubmed-author:LiuXiaoshunXlld:pubmed
pubmed-article:20020305pubmed:authorpubmed-author:SzelidZsoltZlld:pubmed
pubmed-article:20020305pubmed:authorpubmed-author:VermeerschPie...lld:pubmed
pubmed-article:20020305pubmed:authorpubmed-author:PellensMarijk...lld:pubmed
pubmed-article:20020305pubmed:authorpubmed-author:PokreiszPeter...lld:pubmed
pubmed-article:20020305pubmed:authorpubmed-author:MarsboomGlenn...lld:pubmed
pubmed-article:20020305pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20020305pubmed:volume105lld:pubmed
pubmed-article:20020305pubmed:ownerNLMlld:pubmed
pubmed-article:20020305pubmed:authorsCompleteYlld:pubmed
pubmed-article:20020305pubmed:pagination169-79lld:pubmed
pubmed-article:20020305pubmed:meshHeadingpubmed-meshheading:20020305...lld:pubmed
pubmed-article:20020305pubmed:meshHeadingpubmed-meshheading:20020305...lld:pubmed
pubmed-article:20020305pubmed:meshHeadingpubmed-meshheading:20020305...lld:pubmed
pubmed-article:20020305pubmed:meshHeadingpubmed-meshheading:20020305...lld:pubmed
pubmed-article:20020305pubmed:meshHeadingpubmed-meshheading:20020305...lld:pubmed
pubmed-article:20020305pubmed:meshHeadingpubmed-meshheading:20020305...lld:pubmed
pubmed-article:20020305pubmed:meshHeadingpubmed-meshheading:20020305...lld:pubmed
pubmed-article:20020305pubmed:meshHeadingpubmed-meshheading:20020305...lld:pubmed
pubmed-article:20020305pubmed:meshHeadingpubmed-meshheading:20020305...lld:pubmed
pubmed-article:20020305pubmed:meshHeadingpubmed-meshheading:20020305...lld:pubmed
pubmed-article:20020305pubmed:meshHeadingpubmed-meshheading:20020305...lld:pubmed
pubmed-article:20020305pubmed:meshHeadingpubmed-meshheading:20020305...lld:pubmed
pubmed-article:20020305pubmed:meshHeadingpubmed-meshheading:20020305...lld:pubmed
pubmed-article:20020305pubmed:year2010lld:pubmed
pubmed-article:20020305pubmed:articleTitleCardioselective nitric oxide synthase 3 gene transfer protects against myocardial reperfusion injury.lld:pubmed
pubmed-article:20020305pubmed:affiliationVesalius Research Center, Flanders Institute for Biotechnology (VIB), Leuven, Belgium.lld:pubmed
pubmed-article:20020305pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20020305pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:20020305pubmed:publicationTypeValidation Studieslld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:20020305lld:pubmed